Your fact-checks will appear here
GLP-1–type agents have established class concerns for pancreatitis and gallbladder disease.
Dr. Ania M. Jastreboff has authored peer‑reviewed reviews and clinical trial publications that situate GLP‑1 receptor agonists within modern obesity therapeutics and has led high‑profile clinical tria...
Clinical trials and systematic reviews consistently find that weight regain after stopping GLP‑1 and other weight‑loss medications is common and often rapid: pooled analyses project return to baseline...
Continuous glucose monitors (CGMs) and newer glucose-lowering agents such as GLP‑1 receptor agonists and SGLT2 inhibitors promise better outcomes, but their uptake in underserved populations is constr...
Tirzepatide is a dual GIP/GLP‑1 receptor agonist approved for type 2 diabetes and chronic weight management that shows substantial efficacy but carries a predictable cluster of adverse effects—primari...
Intensive, evidence-based lifestyle interventions—centering nutrition, physical activity, sleep, stress management, social support, and avoidance of risky substances—consistently improve glycemic cont...
Randomized-trial evidence shows that structured intensive lifestyle programs can induce remission of type 2 diabetes in a meaningful minority of participants, GLP‑1 receptor agonists produce larger sh...
Randomized trials show two contrasting pathways to diabetes remission and weight loss: intensive very low calorie diets (VLCDs) can produce drug‑off remission with lasting benefit in protocolized prog...
Guidelines converge on a risk‑based, not purely glycemia‑based, choice: SGLT2 inhibitors are recommended for cardiorenal protection down to low eGFR thresholds (often ≥20 mL/min/1.73 m2) despite reduc...
Berberine is the best‑documented botanical tied to GLP‑1 biology: laboratory and animal studies show it can stimulate GLP‑1 secretion via bitter‑taste receptor and PLC‑dependent pathways and through a...
The 2026 ADA Standards of Care adopt a pragmatic, evidence-rooted definition of type 2 diabetes remission based on sustained normal glycemia off glucose‑lowering therapy and pair this definition with ...
Reputable, evidence-based management of type 2 diabetes blends lifestyle intervention, weight management (including bariatric surgery when appropriate), individualized pharmacotherapy, diabetes techno...
Stopping semaglutide commonly triggers substantial weight regain: randomized trials and extensions show most people regain the majority of lost weight within a year to two years after drug withdrawal ...
Bydureon (exenatide extended‑release) is a once‑weekly injectable GLP‑1 receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and certai...
Yale School of Medicine has publicly and proactively pushed back against online falsehoods that tie its clinicians to so‑called weight‑loss “tricks,” issuing explicit denials on departmental and cente...
The phrase “goth” is ambiguous; reporting suggests the intended contrast is between GLP‑1 receptor agonists (weight‑loss peptides) and growth‑hormone (GH)–stimulating peptides or GH itself, so analysi...
There are legitimate, FDA‑approved treatments for type 2 diabetes that have evidence of producing remission—most strongly metabolic/bariatric surgery and intentional substantial weight loss through st...
Randomized trials show GLP‑1 and GLP‑1/GIP drugs (like semaglutide and tirzepatide) produce substantial weight loss and short‑term improvements in cardiometabolic markers while on treatment, but those...
Tirzepatide — a dual GIP and GLP‑1 receptor agonist — produces larger average weight losses in randomized trials than single‑receptor GLP‑1 drugs such as semaglutide and liraglutide, with dose‑depende...
Over‑the‑counter “fat‑loss” supplements generally produce small, inconsistent benefits and are poorly regulated, while bona fide medical alternatives include prescription medications with demonstrated...